CytRx' purified RheothRxpf for sickle cell crisis awaiting FDA Phase III trial green light.
Executive Summary
CYTRx' "PURIFIED" RHEOTHRx TRIAL FOR SICKLE CELL CRISIS AWAITING FDA GO-AHEAD to begin Phase III clinical studies in the first quarter of 1997, company President and CEO Jack Luchese said during an Aug. 27 investor conference call. CytRx' RheothRxpf (polaxamer 188 N.F.) is a "purified version of the commercial grade" of the non-ionic copolymer surfactant rheologic compound used in earlier clinical trials conducted by CytRx and Glaxo Wellcome.